Protagonist Therapeutics (NASDAQ:PTGX) CFO Asif Ali Sells 1,750 Shares

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) CFO Asif Ali sold 1,750 shares of the firm’s stock in a transaction that occurred on Monday, April 20th. The shares were sold at an average price of $105.47, for a total transaction of $184,572.50. Following the completion of the sale, the chief financial officer owned 59,003 shares in the company, valued at $6,223,046.41. This represents a 2.88% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Asif Ali also recently made the following trade(s):

• On Thursday, March 26th, Asif Ali sold 24,765 shares of Protagonist Therapeutics stock. The stock was sold at an average price of $104.24, for a total transaction of $2,581,503.60.
• On Tuesday, January 27th, Asif Ali sold 46,203 shares of Protagonist Therapeutics stock. The stock was sold at an average price of $83.13, for a total transaction of $3,840,855.39.

Protagonist Therapeutics Stock Performance

Shares of NASDAQ:PTGX opened at $105.89 on Wednesday. The firm has a market cap of $6.76 billion, a PE ratio of -51.65 and a beta of 2.12. The firm’s fifty day moving average is $95.92 and its 200-day moving average is $87.50. Protagonist Therapeutics, Inc. has a 52 week low of $41.28 and a 52 week high of $107.84.

Protagonist Therapeutics (NASDAQ:PTGX) last issued its quarterly earnings results on Wednesday, February 25th. The company reported ($0.69) EPS for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.16). The business had revenue of $7.44 million for the quarter, compared to analyst estimates of $14.92 million. Protagonist Therapeutics had a negative return on equity of 19.89% and a negative net margin of 282.83%. Sell-side analysts forecast that Protagonist Therapeutics, Inc. will post 1.02 EPS for the current year.

Hedge Funds Weigh In On Protagonist Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Smartleaf Asset Management LLC lifted its holdings in Protagonist Therapeutics by 11.6% in the third quarter. Smartleaf Asset Management LLC now owns 1,403 shares of the company’s stock valued at $91,000 after buying an additional 146 shares during the period. Farther Finance Advisors LLC increased its stake in Protagonist Therapeutics by 110.6% in the fourth quarter. Farther Finance Advisors LLC now owns 297 shares of the company’s stock valued at $26,000 after purchasing an additional 156 shares in the last quarter. Oregon Public Employees Retirement Fund increased its stake in Protagonist Therapeutics by 1.5% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 13,393 shares of the company’s stock valued at $1,170,000 after purchasing an additional 193 shares in the last quarter. Maryland State Retirement & Pension System increased its stake in Protagonist Therapeutics by 2.3% in the fourth quarter. Maryland State Retirement & Pension System now owns 8,603 shares of the company’s stock valued at $751,000 after purchasing an additional 196 shares in the last quarter. Finally, PNC Financial Services Group Inc. increased its stake in Protagonist Therapeutics by 8.1% in the fourth quarter. PNC Financial Services Group Inc. now owns 2,959 shares of the company’s stock valued at $258,000 after purchasing an additional 221 shares in the last quarter. Institutional investors and hedge funds own 98.63% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently commented on PTGX shares. Citizens Jmp lifted their price target on shares of Protagonist Therapeutics from $102.00 to $112.00 and gave the stock a “market outperform” rating in a report on Thursday, February 26th. Truist Financial lifted their price target on shares of Protagonist Therapeutics from $110.00 to $121.00 and gave the stock a “buy” rating in a report on Tuesday, April 14th. Johnson Rice reiterated a “buy” rating on shares of Protagonist Therapeutics in a report on Wednesday, March 18th. Leerink Partners lifted their price target on shares of Protagonist Therapeutics from $107.00 to $110.00 and gave the stock an “outperform” rating in a report on Thursday, March 19th. Finally, Barclays boosted their target price on shares of Protagonist Therapeutics from $113.00 to $119.00 and gave the company an “overweight” rating in a report on Thursday, March 19th. Thirteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Protagonist Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $108.15.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral ?4?7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.